NASDAQ$INVA
Innoviva Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported strong revenues from royalty and product portfolios, executed key corporate objectives and FDA advisory committee voted in support of sulbactam-durlobactam approval.
Innoviva reported strong Q1 2023 results with significant revenue from royalties and product sales. Net income increased to $34.9 million, and the company repurchased $40.3 million in common stock and paid off $96.2 million in convertible notes.
- Received $60.3 million in GSK royalties, $11.5 million in net product revenues, and $8.0 million in license revenue.
- Repurchased $40.3 million of common stock and paid off $96.2 million of 2023 convertible notes.
- Net income was $34.9 million, or $0.51 basic per share.
- Cash and cash equivalents totaled $144.0 million.
Headline financials
Revenue & EPS history
Innoviva · Revenue · Quarterly
$76.4M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
+1.4%
Avg return
Earnings day
+2.6%
Avg return
5 days after
+2.8%
Avg return
30 days after
55%
35 / 64 earnings
Positive
+19.4%
Q1 2012
Best reaction
-15.1%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.6% | -0.6% | -0.6% | |
| Q4 2025 | -2.7% | -8.0% | -6.5% | |
| Q3 2025 | +13.1% | +20.1% | +13.8% | |
| Q1 2025 | -0.9% | -2.6% | +15.2% | |
| Q4 2024 | -2.0% | -1.8% | +1.6% | |
| Q3 2024 | +2.9% | +3.6% | -2.0% | |
| Q2 2024 | +1.6% | -3.6% | +2.1% | |
| Q1 2024 | -1.5% | +4.2% | +3.9% | |
| Q4 2023 | -0.7% | -3.1% | -0.7% | |
| Q3 2023 | +7.0% | +10.0% | +12.7% | |
| Q2 2023 | -1.3% | +1.3% | -4.0% | |
| Q1 2023 | +4.5% | +8.5% | +17.5% | |
| Q4 2022 | -5.2% | -8.3% | -7.0% | |
| Q3 2022 | +5.1% | +2.6% | +2.5% | |
| Q2 2022 | -1.7% | -1.3% | -8.0% | |
| Q1 2022 | +0.9% | -5.2% | -10.2% | |
| Q4 2021 | +13.7% | +24.5% | +19.2% | |
| Q3 2021 | +8.8% | +9.2% | +6.3% | |
| Q2 2021 | +6.3% | +10.2% | +10.7% | |
| Q1 2021 | +0.9% | +0.7% | +16.2% | |
| Q4 2020 | +1.0% | +1.3% | -7.3% | |
| Q3 2020 | +11.3% | +6.4% | +12.7% | |
| Q2 2020 | +0.4% | +0.7% | -15.0% | |
| Q1 2020 | +5.3% | -0.2% | +3.7% | |
| Q4 2019 | +3.5% | +3.5% | -6.1% | |
| Q3 2019 | +6.2% | +10.8% | +23.2% | |
| Q2 2019 | -15.1% | -10.4% | -16.1% | |
| Q1 2019 | +6.5% | +6.6% | -2.6% | |
| Q4 2018 | -3.3% | -6.1% | -14.2% | |
| Q3 2018 | +2.3% | +7.7% | +22.6% | |
| Q2 2018 | -1.2% | +1.5% | +1.3% | |
| Q1 2018 | -2.9% | -0.3% | -1.5% | |
| Q4 2017 | +8.5% | +19.5% | +14.2% | |
| Q3 2017 | -11.9% | -14.0% | -4.5% | |
| Q2 2017 | +4.3% | +4.7% | -2.1% | |
| Q1 2017 | -8.3% | -9.6% | -5.3% | |
| Q4 2016 | +1.7% | +7.9% | +15.8% | |
| Q3 2016 | -1.6% | +4.2% | +12.9% | |
| Q2 2016 | +9.2% | +8.9% | -3.5% | |
| Q1 2016 | -1.0% | — | — | |
| Q4 2015 | +14.6% | — | — | |
| Q3 2015 | +1.1% | — | — | |
| Q2 2015 | -10.8% | — | — | |
| Q1 2015 | -6.3% | — | — | |
| Q4 2014 | +10.8% | — | — | |
| Q3 2014 | -5.0% | — | — | |
| Q2 2014 | +4.5% | — | — | |
| Q1 2014 | -1.1% | — | — | |
| Q4 2013 | -2.1% | — | — | |
| Q3 2013 | +8.3% | — | — | |
| Q2 2013 | -3.7% | — | — | |
| Q1 2013 | +11.3% | — | — | |
| Q4 2012 | -4.9% | — | — | |
| Q3 2012 | -9.4% | — | — | |
| Q2 2012 | -7.1% | — | — | |
| Q1 2011 | -1.9% | — | — | |
| Q1 2012 | +19.4% | — | — | |
| Q4 2011 | +0.8% | — | — | |
| Q3 2011 | +8.6% | — | — | |
| Q2 2011 | +1.3% | — | — | |
| Q4 2010 | -1.1% | — | — | |
| Q3 2010 | +2.7% | — | — | |
| Q2 2010 | +8.0% | — | — | |
| Q1 2010 | -9.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro